Akebia Therapeutics, Inc.
NASDAQ:AKBABiotechnology
+$0.01 today
- Market cap
- $113.54M
- Beta
- 0.25
- P/E (TTM)
- -13.3
- EPS (TTM)
- -$0.08
Volume 7.09M
Average 4.03M
AKBA Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Akebia Therapeutics, Inc.NASDAQ: AKBA
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow turns negative
Q1 FY2026 financing cash flow was -$926K, compared with $74.94M a year earlier. Trailing-twelve-month financing cash flow was -$2.94M. Over 3 fiscal years it compounded at +70.9% a year.
Context
- Financing cash flow amounted to 30.9% of revenue in FY2025, down 0.1 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near -$926K or moves back toward the trailing-twelve-month quarterly average of -$735.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 72.93M USD
- Year-over-year change
- +46.8%
- 4-year CAGR
- -14.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 72.93M | +46.8% |
| FY2024 | 2024-12-31 | 49.66M | +297.0% |
| FY2023 | 2023-12-31 | (25.21M) | -272.7% |
| FY2022 | 2022-12-31 | 14.6M | -89.1% |
| FY2021 | 2021-12-31 | 133.73M | — |
Financing Cash Flow vs competitors
How AKBA compares with its peers on the latest reported figures
- AKBA's LTM Mar 2026 financing cash flow of $2.94M is the smallest of the 10 companies compared; the peer median is $22.93M.
- Its year-over-year change of -102.8% is the 7th highest of 9, against a peer median of +100.6%.
- Financing cash flow amounts to 1.3% of revenue for AKBA, versus a peer median of 16.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $256.78M | -1.3% | +662.8% | — | |
| LTM Mar 2026 | $226.9M | +360.2% | — | — | |
| LTM Mar 2026 | $133.79M | +14802.1% | +19.6% | — | |
| LTM Mar 2026 | $124.44M | +575.7% | +232.1% | 141.0% | |
| LTM Mar 2026 | $42.35M | -151.3% | +13.0% | 34.6% | |
| LTM Dec 2025 | $22.93M | — | — | 19.8% | |
| LTM Mar 2026 | $10.8M | +25.0% | -54.9% | 3.6% | |
| LTM Mar 2026 | $7.03M | -1150.0% | — | 12.1% | |
| LTM Mar 2026 | $6.43M | +176.3% | -62.0% | 11.6% | |
| LTM Mar 2026 | $2.94M | -102.8% | +70.9% | 1.3% | |
| Peer median (excluding AKBA) | $22.93M | +100.6% | +16.3% | 16.0% | |
Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (282.02M) | (92.56M) | (51.93M) | (69.41M) | (5.35M) |
| Depreciation & Amortization | 36.13M | 37.7M | 41.85M | 37.5M | 1.27M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 22.74M | 17.85M | 9.32M | 7.78M | 11.28M |
| Change in Working Capital | (105.61M) | (1.44M) | (20.73M) | (39.68M) | 16.47M |
| Accounts Receivables | (24.03M) | 11.7M | 994K | 4.05M | (14.14M) |
| Inventory | (24.95M) | 19.79M | (2.54M) | (28.4M) | (23.13M) |
| Accounts Payables | (11.74M) | 1.5M | (5.24M) | (1.36M) | 3.08M |
| Other Working Capital | (44.9M) | (34.42M) | (13.94M) | (13.96M) | 50.66M |
| Other Non-Cash Items | 98.54M | (34.7M) | (1.9M) | 23.15M | 44.31M |
| Operating Cash Flow | (252.97M) | (73.15M) | (23.38M) | (40.66M) | 67.99M |
| Capital Expenditures | (59K) | (114K) | 0 | (33K) | (291K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 40M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (7.93M) |
| Investing Cash Flow | 39.94M | (114K) | 0 | (33K) | (7.93M) |
| Debt Repayment | 44.78M | (33M) | (32M) | 7.9M | 4.63M |
| Common Stock Issued | 88.95M | 7.53M | 6.79M | 42.65M | 68.36M |
| Common Stock Repurchased | 0 | 0 | 0 | (1.27M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 40.07M | 1K | 385K | (63K) |
| Financing Cash Flow | 133.73M | 14.6M | (25.21M) | 49.66M | 72.93M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (79.29M) | (58.67M) | (48.59M) | 8.97M | 132.99M |
| Free Cash Flow | (253.02M) | (73.27M) | (23.38M) | (40.69M) | 67.99M |
Akebia Therapeutics, Inc.
NASDAQ:AKBA
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.